PACK-CXL

A new ELZA review in Die Ophthalmologie examines the mechanisms, clinical evidence, protocol selection, and indications for PACK-CXL in infectious keratitis.
Dual chromophore PACK-CXL treatment using riboflavin/UV-A and rose bengal/green light may offer an effective solution for refractory Acanthamoeba keratitis.
Expert review in Eyenet of corneal cross-linking as an adjunctive treatment for infectious keratitis and corneal melting.
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.
The article by Lu et al. reports an in vitro study, conducted to determine whether high-fluence PACK-CXL can be accelerated while still maintaining its antibacterial efficacy. The study found that high-fluence PACK-CXL did indeed decrease the bacterial concentration of several clinically significant bacterial strains, including S. aureus, P. aeruginosa, and S. epidermidis. These strains are commonly implicated in bacterial keratitis and contact lens-associated keratitis. Furthermore, the authors found that higher total fluence PACK-CXL protocols led to a corresponding increase in bacterial killing ratio (BKR).
Prof. Hafezi reviews the CXL at the Slit Lamp technique in US Ophthalmic Review
Nikki Hafezi's successful launch of slit lamp cross-linking technology.
Short introduction video to the C-eye device and Ribo-Ker riboflavin solution.
Speaker: Prof. Farhad Hafezi, ELZA Institute
Meeting: Hellenic Society for Intraocular Implants and Refractive Surgery (HSIOIRS)
Date: March 2021
Language: English
 
Summary: Prof. Hafez gives on overview about the current state of CXL technology at the annual Hellenic HSOIRS meeting 2021